

August 25, 2025

The Honorable Howard Lutnick
Secretary of Commerce
Attention: Bureau of Industry and Security
Office of Strategic Industries and Economic Security
U.S. Department of Commerce
14th Street and Constitution Avenue, N.W.
Washington, DC 20230

Ambassador Jamieson Greer
U.S. Trade Representative
Office of the U.S. Trade Representative
600 17th St., N.W.
Washington, D.C. 20508

Dear Secretary Lutnick and Ambassador Greer,

We, the undersigned patient advocacy groups, write to share our continued concerns about potential tariffs on imported medicines, particularly regarding the recent US-EU joint statement on a “Framework on an Agreement on Reciprocal, Fair, and Balanced Trade”.

We are particularly concerned regarding the proposed 15 percent tariff on all imported medicines from Europe. We respectfully request that you exempt Europe and other allied nations that do not pose a threat to U.S. security from any Section 232 tariffs on medicines and active pharmaceutical ingredients.

Collectively, we represent millions of patients battling hundreds of diseases who depend on these imported medications. Patients do not choose their diagnosis or their prescribed course of treatment, and they do not want the government to pick winners and losers when it comes to which medications they rely upon. Because European-made drugs often have no therapeutic equivalent, patients may not have the option to switch to an alternative and could be forced to absorb the higher cost or go without life-changing therapies. Even worse, industry participants and other experts have warned that tariffs will result in drug shortages, leaving some Americans without access to treatment altogether.

The ongoing negotiations surrounding pharmaceutical tariffs represent more than just a trade dispute; they are a pivotal moment that will shape global healthcare, innovation, and patient access to critical medicines. Tariffs would translate into higher out-of-pocket costs and likely higher health insurance premiums for Americans. The United States currently produces [53%](#) of the active pharmaceutical ingredients used in Americans' prescriptions. [More than half](#) of these ingredients come from allies in Europe and India. Moreover, [eight in 10](#) U.S. biotech firms predict that it would take at least a year to find new, domestic suppliers in the event of tariffs, during which time their manufacturing capacity could be severely constrained. The patients we represent are deeply concerned that these supply chain disruptions caused by tariffs will result in shortages of life-saving treatments.

We support the goal of expanding domestic pharmaceutical manufacturing, but building new plants and establishing new domestic supply chains are long-term undertakings that could take years to accomplish. In the meantime, widespread tariffs would inflict immediate harm on patients, increase health care spending, and heighten the risk of life-threatening drug shortages.

Patient lives depend on affordable, accessible medications. These tariffs are not just an economic issue - they are a matter of human health and survival. We urge you to maintain the long-standing precedent of exempting medicines from trade penalties.

Sincerely,

Acromegaly Community
Adrenal Insufficiency United
Adult Congenital Heart Association
AiArthritis
Alliance for Aging Research
American Behcet's Disease Association
American Partnership For Eosinophilic Disorders
Applied Pharmacy Solutions
APS Foundation of America
Autoimmune Association
Biomarker Collaborative
Caring Ambassadors Program
Celiac Disease Foundation
Chronic Care Policy Alliance
Coalition of State Rheumatology Organizations
Colorectal Cancer Alliance
Crohn's & Colitis Foundation
CURED Nfp (Campaign Urging Research for Eosinophilic Diseases)
Diabetes Leadership Council
Diabetes Patient Advocacy Coalition
Eosinophilic & Rare Disease Cooperative
Exon 20 Group
Gaucher Community Alliance
GBS|CIDP Foundation International
Global Allergy & Airways Patient Platform
Healthy Men Inc.
HealthyWomen
HIV+Hepatitis Policy Institute
HS Connect
ICAN, International Cancer Advocacy Network
Immune Deficiency Foundation
Lupus and Allied Diseases Association, Inc.
Lupus Foundation of America
MET Crusaders
Multiple Sclerosis Foundation
National Association For Continence
National Association of Nutrition and Aging Services Programs
National Consumers League
National Infusion Center Association
National Psoriasis Foundation
National Scleroderma Foundation

Neuropathy Action Foundation
Partnership to Fight Chronic Disease
PDL1 Amplifieds
Phaware Global Association
Project Sleep
Pulmonary Hypertension Association
RetireSafe
Sjogren's Foundation
TED COMMUNITY ORGANIZATION
The National Adrenal Diseases Foundation
wAIHA Warriors
We Are ILL